Advertisement

Preeclampsia pp 239-251 | Cite as

Pravastatin for Preeclampsia Prevention and Treatment

  • Guillermina GirardiEmail author
Chapter
Part of the Comprehensive Gynecology and Obstetrics book series (CGO)

Abstract

Preeclampsia is a significant, multifactorial, multiorgan disease affecting 5–8% of all pregnancies and leading cause of maternal and fetal mortality. Despite improvements in the diagnosis, there is no effective method of prevention and treatment. While studies in women are of critical importance, investigation of pathological mechanisms in pregnant women is necessarily limited and the ability to establish cause and effect relationships, difficult. Mouse models were invaluable tools in the identification of pravastatin as a potential treatment to prevent pregnancy complications associated with placental dysfunction such as preeclampsia and intrauterine growth restriction.

Numerous epidemiological studies provided robust evidence demonstrating that pravastatin exposure during pregnancy does not affect fetal development. Several pilot studies suggest that pravastatin may be a good option to prevent and treat preeclampsia in women. A randomized clinical trial is necessary to confirm the effectiveness of pravastatin to treat preeclampsia.

Keywords

Preeclampsia Obstetric antiphospholipid syndrome Placental insufficiency Pravastatin 

References

  1. 1.
    Di Simone N, Meroni PL, D’Asta M, et al. Pathogenic role of antibeta2glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update. 2015;21:97–118.CrossRefGoogle Scholar
  2. 2.
    D’Ippolito S, Di Simone N, Di Nicuolo F, et al. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. Am J Reprod Immunol. 2007;58:150–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Bertolaccini ML, Contento G, Lennen R, et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun. 2016;75:30–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Girardi G, Fraser J, Lennen R, Vontell R, Jansen M, Hutchison G. Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO) – conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development. Mol Psychiatry. 2015;20:1017–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110(7):2423–31.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest. 2008;118:3453–61.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Balan A, Szaingurten-Solodkin I, Swissa SS, Feinshtein V, Huleihel M, Holcberg G, Dukler D, Beharier O. The effects of pravastatin on the normal human placenta: lessons from ex-vivo models. PLoS One. 2017;12(2):e0172174.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GD, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013;209(4):373.e1–5.CrossRefGoogle Scholar
  10. 10.
    Zarek J, DeGorter MK, Lubetsky A, Kim RB, Laskin CA, Berger H, Koren G. The transfer of pravastatin in the dually perfused human placenta. Placenta. 2013;34(8):719–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Agostinis C, Bulla R, Tripodo C, Gismondi A, Stabile H, Bossi F, Guarnotta C, Garlanda C, De Seta F, Spessotto P, Santoni A, Ghebrehiwet B, Girardi G, Tedesco F. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol. 2010;185(7):4420–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58(4):716–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One. 2010;5(10):e13663.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31(1):33–46.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GD, Saade GR. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010;116(1):114–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Saad AF, Diken ZM, Kechichian TB, et al. Pravastatin effects on placental prosurvival molecular pathways in a mouse model of preeclampsia. Reprod Sci. 2016;23:1593–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108(4):1451–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, Regal JF, Gilbert JS. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension. 2013;61(5):1103–10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol. 1996;10:439–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol. 2014;101–102:161–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Cleary KL, Roney K, Costantine MM. Challenges of studying drugs in pregnancy off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol. 2014;38(8):523–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynecol Can. 2014;36(6):506–9.CrossRefGoogle Scholar
  24. 24.
    Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. J Clin Lipidol. 2016;10(5):1081–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Bateman BT, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lecarpentier E, et al. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;72(6):773–88.CrossRefPubMedGoogle Scholar
  27. 27.
    Winterfeld U, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013;120(4):463–71.CrossRefPubMedGoogle Scholar
  28. 28.
  29. 29.
    Costantine MM, Clearly K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR, Haas DM, Haneline LS, Caritis SN, Venkataramanan R, West H, D’Alton M, Hankins G, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1–720.e17.CrossRefGoogle Scholar
  30. 30.
    Lefkou E, Mamopoulos A, Fragakis N, Dagklis T, Vosnakis C, Nounopoulos E, Rousso D, Girardi G. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension. 2014;63(5):e118–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, Hastie R, Onda K, Kaitu’u-Lino TJ. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66:687–97.CrossRefPubMedGoogle Scholar
  32. 32.
    Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127(Suppl 3):S72–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933–40.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Laskin CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36(2):279–87.CrossRefPubMedGoogle Scholar
  35. 35.
    Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614–20.PubMedGoogle Scholar
  36. 36.
    Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long term clinical trials: prospective pravastatin pooling (PPP) project. Circulation. 2002;105(20):2341–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Division of Women HealthKing’s CollegeLondonUnited Kingdom

Personalised recommendations